Related Experiment Video
Updated: Jul 12, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
Antibody-drug conjugates and the need for third-modality regulatory science
Ning Jiang1, Jun-Jie Mao2, Xing-Yu Zhou1
1Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
None:
ADCs challenge conventional biologic and small-molecule framework regulation because their performance emerges from integrated antibody, linker, payload, and manufacturing attributes. This commentary proposes a risk-based third-modality science combining product-level assessment, component-specific scrutiny, platform evidence, and life cycle comparability to support ADC innovation, manufacturing flexibility, patient access, and regulatory rigor.
Related Concept Videos
Drug Regulation
Drug Products: Biologics, Biosimilars and Interchangeables
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Principles of Drug Action
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Modified-Release Drug Delivery Systems: Site-Targeted
